Serum protein signature of coronary artery disease in type 2 diabetes mellitus.
Adipokines
Apolipoproteins
Coronary artery diseases
Cytokines/chemokines
Metabolic hormones and biomarkers
Type 2 diabetes mellitus
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
24 01 2019
24 01 2019
Historique:
received:
06
09
2018
accepted:
21
12
2018
entrez:
25
1
2019
pubmed:
25
1
2019
medline:
2
4
2020
Statut:
epublish
Résumé
Coronary artery disease (CAD) is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). The purpose of the present study was to discriminate the Indian CAD patients with or without T2DM by using multiple pathophysiological biomarkers. Using sensitive multiplex protein assays, we assessed 46 protein markers including cytokines/chemokines, metabolic hormones, adipokines and apolipoproteins for evaluating different pathophysiological conditions of control, T2DM, CAD and T2DM with CAD patients (T2DM_CAD). Network analysis was performed to create protein-protein interaction networks by using significantly (p < 0.05) altered protein markers in each disease using STRING 10.5 database. We used two supervised analysis methods i.e., between class analysis (BCA) and principal component analysis (PCA) to reveals distinct biomarkers profiles. Further, random forest classification (RF) was used to classify the diseases by the panel of markers. Our two supervised analysis methods BCA and PCA revealed a distinct biomarker profiles and high degree of variability in the marker profiles for T2DM_CAD and CAD. Thereafter, the present study identified multiple potential biomarkers to differentiate T2DM, CAD, and T2DM_CAD patients based on their relative abundance in serum. RF classified T2DM based on the abundance patterns of nine markers i.e., IL-1β, GM-CSF, glucagon, PAI-I, rantes, IP-10, resistin, GIP and Apo-B; CAD by 14 markers i.e., resistin, PDGF-BB, PAI-1, lipocalin-2, leptin, IL-13, eotaxin, GM-CSF, Apo-E, ghrelin, adipsin, GIP, Apo-CII and IP-10; and T2DM _CAD by 12 markers i.e., insulin, resistin, PAI-1, adiponectin, lipocalin-2, GM-CSF, adipsin, leptin, Apo-AII, rantes, IL-6 and ghrelin with respect to the control subjects. Using network analysis, we have identified several cellular network proteins like PTPN1, AKT1, INSR, LEPR, IRS1, IRS2, IL1R2, IL6R, PCSK9 and MYD88, which are responsible for regulating inflammation, insulin resistance, and atherosclerosis. We have identified three distinct sets of serum markers for diabetes, CAD and diabetes associated with CAD in Indian patients using nonparametric-based machine learning approach. These multiple marker classifiers may be useful for monitoring progression from a healthy person to T2DM and T2DM to T2DM_CAD. However, these findings need to be further confirmed in the future studies with large number of samples.
Sections du résumé
BACKGROUND
Coronary artery disease (CAD) is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). The purpose of the present study was to discriminate the Indian CAD patients with or without T2DM by using multiple pathophysiological biomarkers.
METHODS
Using sensitive multiplex protein assays, we assessed 46 protein markers including cytokines/chemokines, metabolic hormones, adipokines and apolipoproteins for evaluating different pathophysiological conditions of control, T2DM, CAD and T2DM with CAD patients (T2DM_CAD). Network analysis was performed to create protein-protein interaction networks by using significantly (p < 0.05) altered protein markers in each disease using STRING 10.5 database. We used two supervised analysis methods i.e., between class analysis (BCA) and principal component analysis (PCA) to reveals distinct biomarkers profiles. Further, random forest classification (RF) was used to classify the diseases by the panel of markers.
RESULTS
Our two supervised analysis methods BCA and PCA revealed a distinct biomarker profiles and high degree of variability in the marker profiles for T2DM_CAD and CAD. Thereafter, the present study identified multiple potential biomarkers to differentiate T2DM, CAD, and T2DM_CAD patients based on their relative abundance in serum. RF classified T2DM based on the abundance patterns of nine markers i.e., IL-1β, GM-CSF, glucagon, PAI-I, rantes, IP-10, resistin, GIP and Apo-B; CAD by 14 markers i.e., resistin, PDGF-BB, PAI-1, lipocalin-2, leptin, IL-13, eotaxin, GM-CSF, Apo-E, ghrelin, adipsin, GIP, Apo-CII and IP-10; and T2DM _CAD by 12 markers i.e., insulin, resistin, PAI-1, adiponectin, lipocalin-2, GM-CSF, adipsin, leptin, Apo-AII, rantes, IL-6 and ghrelin with respect to the control subjects. Using network analysis, we have identified several cellular network proteins like PTPN1, AKT1, INSR, LEPR, IRS1, IRS2, IL1R2, IL6R, PCSK9 and MYD88, which are responsible for regulating inflammation, insulin resistance, and atherosclerosis.
CONCLUSION
We have identified three distinct sets of serum markers for diabetes, CAD and diabetes associated with CAD in Indian patients using nonparametric-based machine learning approach. These multiple marker classifiers may be useful for monitoring progression from a healthy person to T2DM and T2DM to T2DM_CAD. However, these findings need to be further confirmed in the future studies with large number of samples.
Identifiants
pubmed: 30674322
doi: 10.1186/s12967-018-1755-5
pii: 10.1186/s12967-018-1755-5
pmc: PMC6345069
doi:
Substances chimiques
Biomarkers
0
Blood Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17Références
Nature. 1993 Oct 21;365(6448):762-4
pubmed: 8413656
Int J Endocrinol. 2015;2015:390185
pubmed: 26089884
J Vasc Res. 2009;46(6):609-17
pubmed: 19571581
Am J Physiol Cell Physiol. 2016 Aug 1;311(2):C212-24
pubmed: 27281481
Diabetes. 2005 Dec;54 Suppl 2:S11-7
pubmed: 16306328
Front Endocrinol (Lausanne). 2018 Jan 17;9:2
pubmed: 29387042
Circ J. 2007 Jul;71(7):1067-73
pubmed: 17587712
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
BMC Med. 2012 Dec 05;10:157
pubmed: 23216991
Mayo Clin Proc. 1993 Jun;68(6):556-60
pubmed: 8098786
PLoS One. 2015 Apr 07;10(4):e0123344
pubmed: 25848795
Int J Cardiol. 2017 Jan 15;227:331-334
pubmed: 27839822
Am J Physiol Endocrinol Metab. 2013 Dec 1;305(11):E1359-66
pubmed: 24105413
PLoS One. 2015 Apr 20;10(4):e0125270
pubmed: 25894234
Clin Exp Hypertens. 2019;41(7):645-650
pubmed: 30307757
PLoS One. 2015 Jun 22;10(6):e0127112
pubmed: 26098780
Oncotarget. 2017 Jul 25;8(30):50148-50154
pubmed: 28404934
Arterioscler Thromb. 1993 Jan;13(1):1-10
pubmed: 8422330
Br J Pharmacol. 2014 Aug;171(15):3595-603
pubmed: 24697653
JAMA Cardiol. 2018 Sep 1;3(9):799-801
pubmed: 30046821
Circulation. 2000 May 9;101(18):2149-53
pubmed: 10801754
Biomark Med. 2016 Nov;10(11):1141-1151
pubmed: 27611762
Eur J Vasc Endovasc Surg. 2002 Aug;24(2):161-5
pubmed: 12389240
Expert Opin Biol Ther. 2009 Sep;9(9):1177-88
pubmed: 19604125
Cell. 2014 Jul 3;158(1):41-53
pubmed: 24995977
Prev Med. 2002 Jul;35(1):42-7
pubmed: 12079439
Front Immunol. 2012 Nov 15;3:323
pubmed: 23162547
Atherosclerosis. 2006 May;186(1):140-5
pubmed: 16084515
Physiol Genomics. 2007 Nov 14;31(3):402-9
pubmed: 17698927
Clin Chem. 2010 Apr;56(4):666-70
pubmed: 20110448
PLoS One. 2016 Sep 09;11(9):e0162228
pubmed: 27611793
J Cell Mol Med. 2017 Mar;21(3):422-431
pubmed: 27677429
J Pathol. 2002 Jan;196(1):103-12
pubmed: 11748649
Diabet Med. 2003 Oct;20(10):832-7
pubmed: 14510865
N Engl J Med. 2000 Jun 15;342(24):1792-801
pubmed: 10853003
Science. 1993 Jul 23;261(5120):469-72
pubmed: 8332912
J Biol Chem. 1993 Sep 25;268(27):20676-82
pubmed: 8376417
Vascul Pharmacol. 2015 Jul;70:8-14
pubmed: 25737404
J Am Coll Cardiol. 2005 Dec 6;46(11):1978-85
pubmed: 16325028
Front Immunol. 2017 Mar 13;8:273
pubmed: 28348564
Circ J. 2007 Jun;71(6):868-73
pubmed: 17526982
Obesity (Silver Spring). 2011 Dec;19(12):2295-300
pubmed: 21455126
Anadolu Kardiyol Derg. 2009 Apr;9(2):75-83
pubmed: 19357047
Angiology. 2014 Mar;65(3):239-42
pubmed: 24052521
Clin Chem. 2007 Jan;53(1):34-41
pubmed: 17040956
Diabetes Care. 2004 Aug;27(8):1991-7
pubmed: 15277429
PLoS Med. 2006 Jun;3(6):e176
pubmed: 16671834
J Obes. 2012;2012:926857
pubmed: 22811891
Sci Rep. 2015 Jun 26;5:10202
pubmed: 26111974
J Physiol Pharmacol. 2016 Apr;67(2):321-8
pubmed: 27226191
Diabetes. 2001 Mar;50(3):643-51
pubmed: 11246886
Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):363-71
pubmed: 19112165
Cardiovasc Diabetol. 2018 Feb 16;17(1):29
pubmed: 29452596
Heart Lung Circ. 2011 Oct;20(10):647-54
pubmed: 20807681
Dis Markers. 2015;2015:591454
pubmed: 25852220
J Diabetes Complications. 2002 Jul-Aug;16(4):271-6
pubmed: 12126785
Cytokine. 2015 Oct;75(2):280-90
pubmed: 26194067
Biochim Biophys Acta. 2014 Nov;1843(11):2563-2582
pubmed: 24892271
Clin Exp Immunol. 2000 Sep;121(3):437-43
pubmed: 10971508